Diabetes Mellitus Type 2: A Driving Force for Urological Complications

Trends in Endocrinology and Metabolism

Volumn 27, Issue 5, 2016, Pages 249-261

  Sayyid, Rashid K ^a   Fleshner, Neil E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bladder; Kidney; Metformin; Prostate; Testosterone; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DAPAGLIFLOZIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; CANCER PROGNOSIS; CANCER RISK; DIABETES MELLITUS; ERECTILE DYSFUNCTION; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LOWER URINARY TRACT SYMPTOM; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT CARE; PENIS DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; ANIMAL; COMPLICATION; MALE; PROSTATE TUMOR; RENAL CELL CARCINOMA;

ANIMALS; CARCINOMA, RENAL CELL; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; METFORMIN; PROSTATIC NEOPLASMS; URINARY TRACT INFECTIONS;

EID: 84960984053     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.02.006     Document Type: Review

References (99)

1. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 2014, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
2. Canadian Diabetes Association (2015) , Canadian Diabetes Association. http://www.diabetes.ca/.
3. Diabetes in Canada: Facts and Figures from a Public Health Perspective 2012, Public Health Agency of Canada, Public Health Agency of Canada.
4. Watkins P.J., et al. Diabetic complications of non-insulin-dependent diabetes. Diabet. Med. 1987, 4:293-296.
5. Arrellano-Valdez F., et al. A comprehensive review of urologic complications in patients with diabetes. Springerplus 2014, 3:549.
6. Long X.J., et al. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac. J. Cancer Prev. 2012, 13:4097-4100.
7. Lee M., et al. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism 2012, 61:242-249.
8. Tseng C., et al. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011, 34:616-621.
9. Hsieh M.C., et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp. Diabetes Res. 2012, 2012:413782.
10. Park J., et al. Poor glycemic control of diabetes mellitus is associated with higher risk of prostate cancer detection in a biopsy population. PLoS ONE 2014, 8:9.
11. Hong S., et al. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥12)-core prostate biopsy. Prostate 2012, 72:51-57.
12. Moses K., et al. The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis. 2012, 15:70-74.
13. Ye C., et al. Diabetes causes multiple genetic alterations and downregulates expression of DNA repair genes in the prostate. Lab. Invest. 2011, 91:1363-1374.
14. Jian Gang P., et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr. Res. 2015, 40:54-61.
15. de Beer J., et al. Does cancer risk increase with HbA1c, independent of diabetes?. Br. J. Cancer 2014, 110:2361-2368.
16. Xu H., et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2013, 99:241-249.
17. Xu H., et al. Diabetes mellitus reduces prostate cancer risk - no function of age at diagnosis or duration of disease. Asian Pac. J. Cancer Prev. 2013, 14:441-447.
18. Zhang F., et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol. 2012, 49(Suppl. 1):S235-S246.
19. Colmers I., et al. Insulin use and cancer risk in patients with type 2 diabetes; a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012, 38:485-506.
20. Tsilidis K., et al. Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 2015, 136:372-381.
21. Grossmann M., et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1834-1840.
22. Polychronakos C., et al. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate 1991, 19:313-321.
23. Rastmanesh R., et al. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clin. Genitourin. Cancer 2014, 12:143-148.
24. Roden M., et al. Relative hypoleptinemia in patients with type 1 and type 2 diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 2000, 24:976-981.
25. Stattin P., et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J. Clin. Endocrinol. Metab. 2001, 86:1341-1345.
26. Frayling T., et al. A genetic link between type 2 diabetes and prostate cancer. J. Diabetol. 2008, 51:1757-1760.
27. Stevens V., et al. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2010, 70:601-607.
28. Zhang W., et al. Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications. Med. Hypotheses 2010, 74:242-243.
29. Wu C., et al. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis. 2011, 14:326-331.
30. Moreira D., et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011, 22:977-983.
31. Li Q., et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 2010, 21:1025-1032.
32. Mitin T., et al. Diabetes mellitus, race, and the odds of high grade prostate cancer in men treated with radiation therapy. J. Urol. 2011, 186:2233-2237.
33. Ozbek E., et al. Diabetes mellitus and HbA1c levels associated with high grade prostate cancer. Asian Pac. J. Cancer Prev. 2014, 15:2555-2558.
34. Abdollah F., et al. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2011, 14:74-78.
35. Kang J., et al. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82:463-467.
36. Bensimon L., et al. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 2014, 25:329-338.
37. Bhindi B., et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur. Urol. 2015, 67:64-70.
38. Asmar R., et al. Hypertension, obesity, and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013, 16:62-66.
39. Harper W., et al. Pharmacologic management of type 2 diabetes. Can. J. Diabetes 2013, 37(Suppl. 1):S61-S68.
40. Tseng C., et al. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur. J. Cancer 2014, 50:2831-2837.
41. Chen-Pin W., et al. Statins and finasteride use differentially modify the impact of metformin on prostate cancer incidence in men with type 2 diabetes. Ann. Transl. Med. Epidemiol. 2014, 1:1004.
42. Franciosi M., et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 2013, 8:e71583.
43. Margel D., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 2013, 31:3069-3075.
44. Rieken M., et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J. Urol. 2014, 32:999-1005.
45. Allott E., et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013, 16:391-397.
46. Chen A.C., et al. Complications of androgen deprivation therapy in men with prostate cancer. Curr. Oncol. Rep. 2004, 6:209-215.
47. Alibhai S., et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 2009, 27:3452-3458.
48. Tsai H., et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J. Urol. 2015, 193:1956-1962.
49. Keating N., et al. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur. Urol. 2014, 65:816-824.
50. Nobes J., et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012, 109:1495-1502.
51. Qu X., et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. Int. Urol. Nephrol. 2014, 46:499-504.
52. Chiu Y., et al. Benign prostatic enlargement is not associated with diabetes: a population-based study. Andrology 2015, 3:933-936.
53. Zhu Z., et al. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer 2013, 13:310.
54. Xu X., et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS ONE 2013, 8:e58079.
55. Yang X., et al. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac. J. Cancer Prev. 2013, 14:2583-2589.
56. Fang H., et al. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observation studies. Diabetes Technol. Ther. 2013, 15:914-922.
57. Tseng C. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011, 54:2009-2015.
58. Tseng C. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 2013, 13:7.
59. Tseng C. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetol. 2014, 51:295-303.
60. Nayan M., et al. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol. Oncol. 2015, 33:386.
61. Rieken M., et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol. Oncol. 2014, 32:49.
62. Rieken M., et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int. 2013, 112:1105-1112.
63. Singh S., et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Am. J. Gastroenterol. 2013, 108:881-891.
64. He S., et al. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol. 2014, 35:2095-2102.
65. Zhu Z., et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res. Clin. Pract. 2012, 98:159-163.
66. Tseng C., et al. A review on thiazolidinediones and bladder cancer in human studies. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2014, 32:1-45.
67. Levin D., et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015, 58:493-504.
68. Larsson S.C., Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 2011, 54:1013-1018.
69. Bao C., et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J. Diabetes Complications 2013, 27:357-364.
70. Tseng C., et al. Type 2 diabetes mellitus and kidney cancer risk: a retrospective cohort analysis of the National Health Insurance. PLoS ONE 2015, 10:e0142480.
71. Chen L., et al. The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies. Medicine 2015, 94:e1055.
72. Liu J., et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol. Oncol. 2013, 31:264-270.
73. Hakimi A., et al. The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can. Urol. Assoc. J. 2013, 7:E687-E691.
74. Psutka S., et al. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol. Oncol. 2015, 33:67.
75. Tseng C., et al. Use of metformin and risk of kidney cancer in patients with type 2 diabetes. Eur. J. Cancer 2016, 52:19-25.
76. Bang W., et al. Type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?. Urology 2014, 84:670-674.
77. Chiu A., et al. Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus. Int. J. Urol. 2012, 19:995-1001.
78. Canda A., et al. Does diabetes affect the distribution and number of interstitial cells and neuronal tissue in the ureter, bladder, prostate, and urethra of humans?. Cent. European J. Urol. 2014, 67:366-374.
79. Kanai A., et al. Do we understand any more about bladder interstitial cell?-ICI-RS 2013. Neurourol. Urodyn. 2014, 33:573-576.
80. Vahabi B., et al. The role of c-kit-positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin-induced diabetic rats. BJU Int. 2011, 107:1480-1487.
81. Fu A., et al. Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes. J. Diabetes Complications 2014, 28:805-810.
82. van der Starre W., et al. Diabetes and the course of febrile urinary tract infection. Diabetes Care 2013, 36:e193-e194.
83. Johnsson K., et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J. Diabetes Complications 2013, 27:473-478.
84. Chen H., et al. Increased risk of urinary tract calculi among patients with diabetes mellitus - a population-based cohort study. Urology 2012, 79:86-92.
85. Sancak E., et al. Do hypertension, diabetes mellitus and obesity increase the risk of severity of nephrolithiasis?. Pak. J. Med. Sci. 2015, 31:566-571.
86. Hartman C., et al. Differences in 24-h urine composition between nephrolithiasis patients with and without diabetes mellitus. BJU Int. 2015, 115:619-624.
87. Torricelli F., et al. Type-2 diabetes and kidney stones: impact of diabetes medications and glycemic control. Urology 2014, 84:544-548.
88. Choi T., et al. Analysis of factors affecting spontaneous expulsion of ureteral stones that may predict unfavorable outcomes during watchful waiting periods: What is the influence of diabetes mellitus on the ureter?. Korean J. Urol. 2015, 56:455-460.
89. Huang Y., et al. Phimosis with preputial fissures as a predictor of undiagnosed type 2 diabetes in adults. Acta Derm. Venereol. 2015, Published online September 9, 2015. 10.2340/00015555-2244.
90. Hijri I., et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J. Diabetes Complications 2012, 26:501-505.
91. Tefekli A., et al. Peyronie's disease: a silent consequence of diabetes mellitus. Asian J. Androl. 2006, 8:75-79.
92. Kendirci M., et al. Diabetes mellitus is associated with severe Peyronie's disease. BJU Int. 2007, 99:383-386.
93. Pavone C., et al. Smoking, diabetes, blood hypertension: possible etiologic role for Peyronie's disease? Analysis in 279 patients with a control group in Sicily. Arch. Ital. Urol. Androl. 2015, 87:20-24.
94. La Vignera S., et al. Andrological characterization of the patient with diabetes mellitus. Minerva Endocrinol. 2009, 34:1-9.
95. Ho C., et al. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men. J. Sex. Med. 2015, 12:389-397.
96. Corona G., et al. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27:557-579.
97. Grossmann M., et al. Low testosterone in men with type 2 diabetes: significance and treatment. J. Clin. Endocrinol. Metab. 2011, 96:2341-2353.
98. Kapoor D., et al. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab. Vasc. Dis. Res. 2008, 5:135-137.
99. Weinberg A., et al. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. J. Sex. Med. 2013, 10:3102-3109.